The National Institute of Neurological Disorders and Stroke tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333:1581–7.Google Scholar

Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 13:1017–25.Google Scholar

Hacke, W, Kaste, M, Fieschi, C, et al. Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352:1245–51.Google Scholar

Hacke, W, Donnan, G, Fieschi, C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363:768–74.Google Scholar

Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359:1317–29.Google Scholar

Albers, G W, Clark, W M, Madden, K P, Hamilton, S A. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke. 2002; 33:493–5.CrossRefGoogle ScholarPubMed

Wahlgren, N, Ahmed, N, Eriksson, N, et al. Safe Implementation of Thrombolysis in Stroke-Monitoring Study Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring STudy (SITS-MOST). Stroke. 2008; 3316–22.Google Scholar

Fonarow, G C, Smith, E E, Saver, J L, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011; 7:750–8.Google Scholar

Mishra, N K, Ahmed, N, Andersen, G, et al. VISTA collaborators; SITS collaborators. Thrombolysis in very elderly people: Controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010; 341:c6046. doi:10.1136.Google Scholar

Intracerebral haemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997; 11: 2109–18.Google Scholar

Saposni, G, Raptis, S, Kapral, M K, et al. Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcome Research Canada Working Group. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke. 2011; 12:3421–8.Google Scholar

Saposnik, G, Fang, J, Kapral, M K, et al. Investigators of the Registry of the Canadian Stroke Network (RCSN); Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012; 5:1315–22.Google Scholar

Mazya, M, Egido, J A, Ford, G A, et al. SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012; 43:1524–31.Google Scholar

Mazya, M V, Bovi, P, Castillo, J, et al. External validation of the SEDAN score for prediction of intracerebral hemorrhage in stroke thrombolysis. Stroke. 2013; 44:1595–600.CrossRefGoogle ScholarPubMed

Butcher, K, Christensen, S, Parsons, M, et al. EPITHET Investigators. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010; 1:72–7.Google Scholar

Diedler, J, Ahmed, N, Sykora, M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010; 2:288–94.Google Scholar

Martinez-Ramirez, S, Delgado-Mederos, R, Marín, R, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: Results from a case-control study and a meta-analysis. J Neurol. 2012; 1:111–18.Google Scholar

Diedler, J, Ahmed, N, Glahn, J, et al. Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg? Stroke. 2011; 6:1615–20.Google Scholar

Putaala, J, Sairanen, T, Meretoja, A, et al. Post-thrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke. Cerebrovasc Dis. 2011; 1:83–92.Google Scholar

Mustanoja, S, Meretoja, A, Putaala, J, et al. Helsinki Stroke Thrombolysis Registry Group. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke. 2011; 1:102–6.Google Scholar

Qureshi, A I, Chaudhry, S A, Hassan, A E, et al. Thrombolytic treatment of patients with acute ischemic stroke related to underlying arterial dissection in the United States. Arch Neurol. 2011; 12:1536–42.Google Scholar

Mazya, M V, Ahmed, N, Ford, G A, et al. Remote or extraischemic intracerebral hemorrhage – an uncommon complication of stroke: Results from the Safe Implementation of Treatments in Stroke – International Stroke Thrombolysis Register. Stroke. 2014; 45:1657–63.Google Scholar

Castellanos, M, Sobrino, T, Millán, M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke. 2007; 6:1855–914.Google Scholar

Albers, G W, Thijs, V N, Wechsler, L, et al. DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006; 5:508–17.Google Scholar

Campbell, B C, Christensen, S, Butcher, K S, et al. EPITHET Investigators. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke. Stroke. 2010; 1:82–8.Google Scholar

Fiehler, J, Albers, G W, Boulanger, J M, et al. MR STROKE Group. Bleeding Risk Analysis in Stroke Imaging before thromboLysis (BRASIL): Pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007; 2738–44.Google Scholar

Dannenberg, S, Scheitz, J F, Rozanski, M, et al. Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2014; 10:2900–5.Google Scholar

Gratz, P P, El-Koussy, M, Hsieh, K, et al. Preexisting cerebral microbleeds on susceptibility-weighted magnetic resonance imaging and post-thrombolysis bleeding risk in 392 patients. Stroke. 2014; 6:1684–8.Google Scholar

Jung, S, Mono, M L, Findling, O, et al. White matter lesions and intra-arterial thrombolysis. J Neurol. 2012; 7:1331–6.Google Scholar

Neumann-Haefelin, T, Hoelig, S, Berkefeld, J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006; 37: 2463–6.Google Scholar

Broderick, J P, Palesch, Y Y, Demchuk, A M, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013; 368:893–903.Google Scholar

Kidwell, C S, Jahan, R, Saver, J L. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013; 368:2434–5.CrossRefGoogle ScholarPubMed

Ciccone, A, Valvassori, L, Nichelatti, M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013; 368:904–13.Google Scholar

Berkhemer, O A, Fransen, P S, Beumer, D, et al. MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015; 1:11–20.CrossRefGoogle Scholar

Goyal, M, Demchuk, A M, Menon, B K, et al. ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 11:1019–30.Google Scholar

Saver, J L, Goyal, M, Bonafe, A, et al. SWIFT PRIME Investigators. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: Protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke. 2015; 3:439–48.Google Scholar

Campbell, B C, Mitchell, P J, Kleinig, T J, et al. EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015; 11:1009–18.Google Scholar

Bang, O Y, Saver, J L, Kim, S J, et al. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke. 2011; 42:2235–9.Google Scholar

Warach, S, Latour, L L. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood–brain barrier disruption. Stroke. 2004; 35:2659–61.CrossRefGoogle ScholarPubMed

Khatri, R, McKinney, A M, Swenson, B, et al. Blood–brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology. 2012; 79:S52–7.Google Scholar

Giraud, M, Cho, T H, Nighoghossian, N, et al. Early blood brain barrier changes in acute ischemic stroke: A sequential MRI study. J Neuroimaging. 2015; 25:959–63.Google Scholar